EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CD74 and MIF in EBV-associated malignancies: diagnostic and therapeutic implications

Takahiro Inoue, Ryusuke Hayashi, Hiroki Komatsuda, Akemi Kosaka, Takayuki Ohkuri, Ryusei Yoshino, Hiroyoshi Nozaki, Shota Sakaue, Hisataka Ominato, Ryosuke Sato, Risa Wakisaka, Michihisa Kono und 8 weitere

Cancer Immunology, Immunotherapy · 18.11.2026

DOI: 10.1007/s00262-026-04620-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 18.11.2026. Verfasst von Takahiro Inoue und 19 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD74 and its ligand, macrophage migration inhibitory factor (MIF), are highly expressed in several malignancies and contribute to tumor progression, making them attractive targets for cancer diagnosis and therapy. However, the expression of CD74 and MIF and their clinicopathological significance remain unclear in Epstein–Barr virus (EBV)-associated malignancies, including nasopharyngeal carcinoma (NPC) and extranodal natural killer/T-cell lymphoma, nasal type (ENKL). In the present study, we demonstrated that CD74 was predominantly expressed by tumor cells in NPC and ENKL tissues. High CD74 expression in NPC was significantly associated with EBV infection. In addition, serum MIF levels were significantly elevated in patients with NPC and ENKL and showed good diagnostic performance in distinguishing patients from healthy controls. Elevated serum MIF levels were also associated with the presence of B symptoms in patients with ENKL. Furthermore, EBV-positive NPC and ENKL cell lines expressed cell-surface CD74 and secreted MIF in a time-dependent manner. Treatment with a CD74-neutralizing antibody significantly reduced the viability of these cell lines, suggesting that CD74/MIF signaling contributes to tumor growth, possibly through an autocrine mechanism. CD74 knockdown in NPC cells induced transcriptomic alterations involving immune- and inflammation-related pathways. Notably, treatment with an anti-CD74 antibody significantly suppressed the growth of established NPC xenografts in mice. Collectively, these findings suggest that CD74 and MIF represent promising diagnostic biomarkers and that therapeutic strategies targeting the CD74/MIF axis may provide a novel treatment approach for EBV-associated malignancies, particularly NPC and ENKL.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Inoue, T., Hayashi, R., Komatsuda, H., Kosaka, A., Ohkuri, T., Yoshino, R., Nozaki, H., Sakaue, S., Ominato, H., Sato, R., Wakisaka, R., Kono, M., Yamaki, H., Ohara, K., Kumai, T., Kishibe, K., Hayashi, T., Takahara, M., Kobayashi, H., & Nagato, T. (2026). CD74 and MIF in EBV-associated malignancies: diagnostic and therapeutic implications. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04620-8

Vancouver

Inoue T, Hayashi R, Komatsuda H, Kosaka A, Ohkuri T, Yoshino R, et al. CD74 and MIF in EBV-associated malignancies: diagnostic and therapeutic implications. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04620-8

BibTeX
@article{Inoue2026,
  author = {Inoue, Takahiro and Hayashi, Ryusuke and Komatsuda, Hiroki and Kosaka, Akemi and Ohkuri, Takayuki and Yoshino, Ryusei and Nozaki, Hiroyoshi and Sakaue, Shota and Ominato, Hisataka and Sato, Ryosuke and Wakisaka, Risa and Kono, Michihisa and Yamaki, Hidekiyo and Ohara, Kenzo and Kumai, Takumi and Kishibe, Kan and Hayashi, Tatsuya and Takahara, Miki and Kobayashi, Hiroya and Nagato, Toshihiro},
  title = {CD74 and MIF in EBV-associated malignancies: diagnostic and therapeutic implications},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04620-8}
}
Kostenlos starten →